Mallinckrodt (MNK) Announces H.P. Acthar Gel Pilot Study Missed Primary Endpoint in SLE
Tweet Send to a Friend
Data presented yesterday by researchers for Mallinckrodt plc (NYSE: MNK) suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
